Information  X 
Enter a valid email address

Company Name matching 'Novo Nordisk A/S'

Date
Time Source
Company
Announcement
26 Nov 2021 6:06 am GNW   Novo Nordisk A/S Novo Nordisk announces impact from Volume Based Procurement for insulin in China
12 Nov 2021 10:57 am GNW   Novo Nordisk A/S Ozempic® 2.0 mg recommended for approval for the treatment of type 2 diabetes by the European Medicines Agency
11 Nov 2021 3:53 pm GNW   Novo Nordisk A/S Wegovy™ recommended for approval for the treatment of obesity by the European regulatory authorities
03 Nov 2021 6:30 am GNW   Novo Nordisk A/S Novo Nordisk's net profit increased by 12% in the first nine months of 2021
29 Oct 2021 2:04 pm GNW   Novo Nordisk A/S Novo Nordisk raises sales and operating profit outlook for 2021
04 Aug 2021 3:41 pm GNW   Novo Nordisk A/S Novo Nordisk's net profit increased by 10% in the first six months of 2021
  3:23 pm GNW   Novo Nordisk A/S Novo Nordisk's net profit increased by 10% in the first six months of 2021
26 Jun 2021 9:30 pm GNW   Novo Nordisk A/S Investigational 2.0 mg dose of Ozempic® (semaglutide) demonstrates superior reductions in blood sugar vs Ozempic® 1.0 mg in adults with type 2 diabetes in a phase 3 trial
04 Jun 2021 7:10 pm GNW   Novo Nordisk A/S Wegovy™ (semaglutide 2.4 mg), the first and only once-weekly GLP-1 therapy for weight management, approved in the US
28 May 2021 3:16 pm GNW   Novo Nordisk A/S Novo Nordisk resubmits once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes for US regulatory approval
07 May 2021 8:31 pm GNW   Novo Nordisk A/S Novo Nordisk A/S – Share repurchase programme
  8:24 pm GNW   Novo Nordisk A/S Novo Nordisk A/S purchases B shares worth DKK 2,586 million from Novo Holdings A/S under the 2021 share repurchase programme
05 May 2021 6:30 am GNW   Novo Nordisk A/S Novo Nordisk's net profit increased by 6% in the first three months of 2021
27 Apr 2021 2:14 pm GNW   Novo Nordisk A/S Novo Nordisk A/S – Reduction of the share capital
21 Apr 2021 2:52 pm GNW   Novo Nordisk A/S Novo Nordisk to initiate phase 3a development in obesity with oral semaglutide
25 Mar 2021 4:12 pm GNW   Novo Nordisk A/S Correction: Resolutions from the Annual General Meeting of Novo Nordisk A/S
22 Mar 2021 9:45 pm GNW   Novo Nordisk A/S Novo Nordisk receives Refusal to File letter for once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes
23 Feb 2021 7:02 am GNW   Novo Nordisk A/S Notice for the Annual General Meeting of Novo Nordisk A/S
03 Feb 2021 6:30 am GNW   Novo Nordisk A/S Novo Nordisk's net profit increased by 8% in 2020
20 Jan 2021 3:07 pm GNW   Novo Nordisk A/S Novo Nordisk files for regulatory approval in the US of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes
29 Dec 2020 11:12 am GNW   Novo Nordisk A/S Novo Nordisk files for EU regulatory approval of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes
18 Dec 2020 7:10 am GNW   Novo Nordisk A/S Novo Nordisk files for EU regulatory approval of once-weekly semaglutide 2.4 mg for weight management
16 Dec 2020 1:07 pm GNW   Novo Nordisk A/S Novo Nordisk to enter phase 3 development in Alzheimer’s disease with oral semaglutide
04 Dec 2020 12:28 pm GNW   Novo Nordisk A/S Novo Nordisk files for US FDA regulatory approval of once-weekly semaglutide 2.4 mg for weight management
17 Nov 2020 2:24 pm GNW   Novo Nordisk A/S Once-weekly semaglutide 2.0 mg demonstrates superior reduction in HbA1c vs once-weekly semaglutide 1.0 mg in people with type 2 diabetes in the SUSTAIN FORTE trial
30 Oct 2020 6:30 am GNW   Novo Nordisk A/S Novo Nordisk's operating profit increased by 6% in Danish kroner and by 7% at constant exchange rates (CER) in the first nine months of 2020
08 Oct 2020 5:40 pm GNW   Novo Nordisk A/S Novo Nordisk raises sales and operating profit outlook for 2020
06 Aug 2020 6:30 am GNW   Novo Nordisk A/S Novo Nordisk's operating profit increased by 9% in Danish kroner and by 8% at constant exchange rates (CER) in the first six months of 2020
29 Jun 2020 6:03 am GNW   Novo Nordisk A/S Rybelsus® approved in Japan for the treatment of type 2 diabetes
18 Jun 2020 3:24 pm GNW   Novo Nordisk A/S Novo Nordisk successfully completes AM833 phase 2 trial and phase 1 combination trial with AM833 and semaglutide in obesity
12 Jun 2020 2:09 pm GNW   Novo Nordisk A/S Semaglutide 2.4 mg shows superior weight loss versus placebo in the phase 3 trials STEP 2 and STEP 3, thereby successfully completing the programme
04 Jun 2020 6:10 pm GNW   Novo Nordisk A/S Novo Nordisk reports weight loss of 14.9% (16.9% if taken as intended) in STEP 1 trial
13 May 2020 4:40 pm GNW   Novo Nordisk A/S Semaglutide 2.4 mg demonstrates superior and sustained weight loss versus placebo and in addition a 17.4% weight loss after 68 weeks in STEP 4 trial
06 May 2020 6:31 am GNW   Novo Nordisk A/S Novo Nordisk's sales increased by 16% in Danish kroner and by 14% at constant exchange rates (CER) to DKK 33.9 billion in the first three months of 2020
28 Apr 2020 3:04 pm GNW   Novo Nordisk A/S Novo Nordisk A/S – Reduction of the share capital
04 Apr 2020 6:24 am GNW   Novo Nordisk A/S Rybelsus® (oral semaglutide) approved for the treatment of adults with type 2 diabetes in the EU
26 Mar 2020 2:30 pm GNW   Novo Nordisk A/S Resolutions from the Annual General Meeting of Novo Nordisk A/S
16 Mar 2020 6:03 pm GNW   Novo Nordisk A/S Novo Nordisk pauses the clinical trials investigating concizumab (anti-TFPI mAB) in haemophilia A and B with or without inhibitors
21 Feb 2020 7:01 am GNW   Novo Nordisk A/S Notice for the Annual General Meeting of Novo Nordisk A/S
05 Feb 2020 6:31 am GNW   Novo Nordisk A/S Novo Nordisk's operating profit increased by 11% in Danish kroner and by 6% at constant exchange rates (CER) in 2019
31 Jan 2020 11:07 am GNW   Novo Nordisk A/S Rybelsus® (oral semaglutide) recommended for approval for the treatment of adults with type 2 diabetes by the European regulatory authorities
16 Jan 2020 10:38 pm GNW   Novo Nordisk A/S Ozempic® approved in the US for CV risk reduction in people with type 2 diabetes and established CVD
30 Dec 2019 8:00 am GNW   Novo Nordisk A/S Novo Nordisk A/S:
20 Nov 2019 7:31 am GNW   Novo Nordisk A/S Novo Nordisk expects to meet its current long-term financial targets and introduces strategic aspirations at the Capital Markets Day 2019
01 Nov 2019 6:31 am GNW   Novo Nordisk A/S Novo Nordisk's operating profit increased by 11% in Danish kroner and by 5% at constant exchange rates (CER) in the first nine months of 2019
16 Aug 2019 1:30 pm GNW   Novo Nordisk A/S Novo Nordisk A/S: Securities lawsuit filed in Denmark against Novo Nordisk
09 Aug 2019 6:31 am GNW   Novo Nordisk A/S Novo Nordisk's operating profit increased by 12% in Danish kroner and by 6% at constant exchange rates (CER) in the first six months of 2019
20 Jun 2019 5:48 pm GNW   Novo Nordisk A/S Esperoct® (turoctocog alfa pegol, N8-GP) approved in the EU
03 May 2019 6:30 am GNW   Novo Nordisk A/S Novo Nordisk's operating profit increased by 14% in Danish kroner and by 8% at constant exchange rates (CER) in the first three months of 2019
26 Apr 2019 3:46 pm GNW   Novo Nordisk A/S Novo Nordisk receives positive opinion from the European regulatory authorities for Esperoct® (turoctocog alfa pegol, N8-GP) for the treatment of haemophilia A
  9:58 am GNW   Novo Nordisk A/S Novo Nordisk files for EU regulatory approval of oral semaglutide for the treatment of type 2 diabetes
24 Apr 2019 5:27 pm GNW   Novo Nordisk A/S Novo Nordisk A/S - Reduction of the share capital
21 Mar 2019 2:58 pm GNW   Novo Nordisk A/S Resolutions from the Annual General Meeting of Novo Nordisk A/S
20 Mar 2019 2:00 pm GNW   Novo Nordisk A/S Novo Nordisk files oral semaglutide for US regulatory approval of glycaemic control, as well as for CV risk reduction for oral semaglutide and Ozempic®
18 Mar 2019 11:02 am GNW   Novo Nordisk A/S Novo Nordisk settles US patent litigation case on Victoza® (liraglutide) with Teva
22 Feb 2019 7:02 am GNW   Novo Nordisk A/S Novo Nordisk: Notice for the Annual General Meeting of Novo Nordisk A/S
19 Feb 2019 5:29 pm GNW   Novo Nordisk A/S Novo Nordisk receives US FDA approval of ESPEROCT® (turoctocog alfa pegol, N8-GP)
05 Feb 2019 7:33 am GNW   Novo Nordisk A/S Novo Nordisk files annual report with the SEC
01 Feb 2019 6:30 am GNW   Novo Nordisk A/S Novo Nordisk's operating profit decreased by 4% in Danish kroner and increased by 3% in local currencies in 2018
23 Nov 2018 3:08 pm GNW   Novo Nordisk A/S Oral semaglutide demonstrates favourable cardiovascular safety profile and significant reduction in cardiovascular death and all-cause mortality in people with type 2 diabetes in the PIONEER 6 trial


Company Announcements Archive »


a d v e r t i s e m e n t